首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1741434

腫瘤微環境市場按癌症類型、標靶、治療、最終用戶和地區分類

Tumor Microenvironment Market, By Cancer Type, By Target, By Therapy, By End User, By Geography

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

腫瘤微環境市場規模在2025年估計為18.7億美元，預計到2032年將達到43.7億美元，2025年至2032年的年複合成長率（CAGR）為12.9%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	18.7億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	12.90%	2032年價值預測	43.7億美元

腫瘤微環境是一個複雜的生態系統，由各種細胞和非細胞成分組成，它們相互作用，在腫瘤的發生和發展中起關鍵作用。這些成分包括免疫細胞、纖維母細胞、細胞外基質、訊號分子等。了解腫瘤微環境對於開發有效治療癌症的標靶治療至關重要。近年來，腫瘤微環境研究引起了廣泛關注，人們認知到癌細胞與其周圍環境之間動態相互作用的重要性。目前已清楚，腫瘤微環境影響各種過程，包括血管生成、免疫反應、轉移和抗藥性。

市場動態：

受多種因素推動，腫瘤微環境市場預計將在未來幾年內實現顯著成長。其中一個主要促進因素是全球癌症發生率的上升。根據世界衛生組織 (WHO) 2020 年的數據，癌症是全球主要死亡原因之一，每年約有 1,000 萬例新病例和 600 萬人死亡。這導致對用於理解和治療癌症的先進方法的需求不斷成長，從而推動了市場的成長。

然而，高昂的研發成本、嚴格的監管要求以及在腫瘤微環境研究中使用動物模型所帶來的倫理問題等因素可能會抑制市場的成長。此外，熟練專家的缺乏以及調查方法缺乏標準化也可能對市場成長構成挑戰。

儘管面臨這些挑戰，腫瘤微環境市場仍蘊藏著巨大的成長機會。多光子顯微鏡和活體成像等成像技術的進步，使研究人員能夠即時、高解析度地研究腫瘤微環境。此外，個人化醫療的興起和精準腫瘤學的日益關注，催生了對能夠洞察腫瘤微環境的生物標記的需求，這進一步推動了市場的成長。

此外，市場參與者正在採取合作等無機策略，預計這將在預測期內推動全球腫瘤微環境市場的成長。例如，2023年3月20日，德國生物技術公司BioNTech SE和臨床階段生物製藥公司OncoC4, Inc.宣布，雙方已達成全球獨家許可和合作協議，以開發和商業化OncoC4的下一代抗CTLA-4單克隆抗體候選藥物ONC-392，作為多種癌症適應症的單一療法或聯合治療。 CTLA-4是一種透過多種機制抑制免疫細胞活性的分子。 OncoC4的CTLA-4候選抗體ONC-392旨在消除腫瘤微環境中的免疫抑制T細胞（調節性T細胞，「Tregs」），並保護健康組織中的Tregs。

本研究的主要特點

本報告對全球腫瘤微環境市場進行了詳細分析，並以 2024 年為基準年，提供了 2025 年至 2032 年預測期內的市場規模和年複合成長率（CAGR%）。
它還揭示了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球腫瘤微環境市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球腫瘤微環境市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
透過分析全球腫瘤微環境市場中使用的各種策略矩陣，相關人員將能夠做出決策。

Thermo Fisher Scientific
Illumina
Danaher Corporation
Merck KGaA
BD Biosciences
Promega Corporation
Bio-Techne Corporation
Bio-Rad Laboratories
Hoffmann-La Roche Ltd
QIAGEN NV
Sartorius AG
PerkinElmer
Miltenyi Biotec
Cell Signaling Technology
BioLegend
Abcam
Takara Bio
Fluidigm Corporation
NanoString Technologies
10x Genomics
Bethyl Laboratories

第 11 章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI6238

Tumor Microenvironment Market is estimated to be valued at USD 1.87 Bn in 2025 and is expected to reach USD 4.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1.87 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	12.90%	2032 Value Projection:	USD 4.37 Bn

The tumor microenvironment is a complex ecosystem consisting of various cellular and non-cellular components that interact with each other and play a crucial role in tumor development and progression. These components include immune cells, fibroblasts, blood vessels, the extracellular matrix, and signaling molecules. Understanding the tumor microenvironment is essential for developing targeted therapies that can effectively treat cancer. The study of the tumor microenvironment has gained significant attention in recent years, as researchers have realized the importance of this dynamic interaction between tumor cells and their surroundings. It is now evident that the tumor microenvironment can influence various processes, such as angiogenesis, immune response, metastasis, and drug resistance.

Market Dynamics:

The tumor microenvironment market is expected to witness significant growth in the coming years, driven by several factors. One of the major drivers is the increasing incidence of cancer worldwide. According to the World Health Organization (WHO), 2020, cancer is one of the leading causes of death globally, with approximately 10 million new cases and 6 million deaths reported annually. This has led to a substantial demand for advanced methods to understand and treat cancer, thereby driving market growth.

However, market growth can be restrained by factors, such as the high cost of research and development, stringent regulatory requirements, and ethical concerns related to the use of animal models in tumor microenvironment studies. Additionally, the limited availability of skilled professionals and the lack of standardization in research methodologies can pose challenges to market growth.

Despite these challenges, the tumor microenvironment market offers significant opportunities for growth. Technological advancements in imaging techniques, such as multiphoton microscopy and intravital imaging, have enabled researchers to study the tumor microenvironment in real-time and high resolution. Moreover, the emergence of personalized medicine and the increasing focus on precision oncology have created a demand for biomarkers that can provide insights into the tumor microenvironment, further driving market growth.

Moreover, market players are engaged in conducting inorganic strategies such as collaborations, and this is expected to increase the growth of the global tumor microenvironment market over the forecast period. For instance, on March 20, 2023, BioNTech SE, a German biotechnology company and OncoC4, Inc., a clinical-stage biopharmaceutical company, announced that they had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4's CTLA-4 antibody candidate, ONC-392, aims to delete immunosuppressive T cells (regulatory T cells, "Tregs") in the tumor microenvironment but spare Tregs in healthy tissues.

Key features of the study:

This report provides in-depth analysis of the global tumor microenvironment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tumor microenvironment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Thermo Fisher Scientific, Illumina, Danaher Corporation, Merck KGaA , BD Biosciences, Promega Corporation, Bio-Techne Corporation , Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Sartorius AG, PerkinElmer, Miltenyi Biotec, Cell Signaling Technology, BioLegend, Abcam, Takara Bio, Fluidigm Corporation, NanoString Technologies, 10x Genomics, and Bethyl Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global tumor microenvironment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor microenvironment market

Detailed Segmentation:

By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Bladder Cancer
- Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
By Target
- T Cells
- Tumor-Associated Macrophages
- Myeloid-Derived Suppressor Cells
- Cancer-Associated Fibroblasts
- Regulatory T Cells
- Others (Tumor-associated neutrophils, Dendritic cells etc.)
By Therapy:
- Monoclonal Antibodies
- Cytokines
- Cancer Vaccines
- Oncolytic Viruses
- Adoptive Cell Therapies
- Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
By End User:
- Biopharmaceutical Companies
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Contract Research Organizations (CROs)
- Others (Academic Institutes and Others)
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Thermo Fisher Scientific
- Illumina
- Danaher Corporation
- Merck KGaA
- BD Biosciences
- Promega Corporation
- Bio-Techne Corporation
- Bio-Rad Laboratories
- F.Hoffmann-La Roche Ltd
- QIAGEN N.V.
- Sartorius AG
- PerkinElmer
- Miltenyi Biotec
- Cell Signaling Technology
- BioLegend
- Abcam
- Takara Bio
- Fluidigm Corporation
- NanoString Technologies
- 10x Genomics
- Bethyl Laboratories

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Tumor Microenvironment, By Cancer Type
- Market Tumor Microenvironment, By Target
- Market Tumor Microenvironment, By Therapy
- Market Tumor Microenvironment, By End User
- Market Tumor Microenvironment, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing cancer prevalence
- High costs associated with reagents
- Adoption of AI and machine learning
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Tumor Microenvironment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Tumor Microenvironment Market , By Cancer Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Tumor Microenvironment Market , By Target, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
T Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Tumor-associated Macrophages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Myeloid-Derived Suppressor Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cancer-Associated Fibroblasts
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Regulatory T Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Tumor-associated neutrophils, Dendritic cells etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Tumor Microenvironment Market , By Therapy, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cancer Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Oncolytic Viruses
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Adoptive Cell Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Tumor Microenvironment Market , By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Academic Institutes and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Tumor Microenvironment Market , By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC Countries
  - Israel
  - South Africa
  - North Africa
  - Central Africa
  - Rest of Middle East

10. Competitive Landscape

Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Illumina
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
BD Biosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Promega Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bio-Techne Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bio-Rad Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
QIAGEN N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sartorius AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
PerkinElmer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Miltenyi Biotec
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Cell Signaling Technology
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
BioLegend
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Abcam
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takara Bio
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Fluidigm Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
NanoString Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
10x Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bethyl Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views